Literature DB >> 31267181

Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?

Michael Froehner1,2, Rainer Koch3, Ulrike Heberling4, Matthias Hübler5, Vladimir Novotny4,6, Angelika Borkowetz4, Manfred P Wirth4, Christian Thomas4.   

Abstract

PURPOSE: There is no consensus on the best comorbidity measure in candidates for radical cystectomy. The aim of this study was to identify tool best suited to identify patients at risk for 90-day or premature long-term non-bladder cancer mortality.
METHODS: We studied 1268 patients who underwent radical cystectomy to identify patients at risk for 90-day and later-than-90-day mortality, respectively. Six classifications were investigated as possible predictors of both types of mortality. Multivariable models including age as continuous variable and each classification separately were calculated. A heuristic ranking was based on the evaluation of the hazard ratios, p values, Akaike's information criteria, and concerning the logit models also the areas under the curve.
RESULTS: The median follow-up was 5.7 years. Within 90 days after surgery, the mortality rate was 4.2%. The greatest independent contribution concerning the prediction of 90-day mortality was seen with the American Society of Anesthesiologists (ASA) physical status classification (classes 3-4 versus 1-2: hazard ratio 7.98, 95% confidence interval 3.54-18.01, p < 0.0001). In the longer term, countable diseases (Canadian Cardiovascular Society classification of angina pectoris, conditions contributing the Charlson score) were of greater importance. The results of heuristic ranking were confirmed by multivariate analyses including age and all classifications together.
CONCLUSIONS: Besides to chronological age, clinicians should pay particular attention to the ASA classification to identify patients at risk for 90-day mortality after radical cystectomy, whereas long-term mortality is more determined by countable comorbid diseases.

Entities:  

Keywords:  90-day mortality; Bladder; Comorbidity; Competing mortality; Competing risk analysis; Cystectomy; Logit model; Proportional hazards model

Mesh:

Year:  2019        PMID: 31267181     DOI: 10.1007/s00345-019-02860-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  12 in total

1.  Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder.

Authors:  Roman Mayr; Mattias May; Thomas Martini; Michele Lodde; Evi Comploj; Armin Pycha; Jenny Strobel; Stefan Denzinger; Wolfgang Otto; Wolfgang Wieland; Maximilian Burger; Hans-Martin Fritsche
Journal:  Eur Urol       Date:  2012-04-12       Impact factor: 20.096

2.  Validation of the Preoperative Score to Predict Postoperative Mortality in Patients Undergoing Radical Cystectomy.

Authors:  Michael Froehner; Rainer Koch; Matthias Hübler; Ulrike Heberling; Vladimir Novotny; Stefan Zastrow; Manfred P Wirth
Journal:  Eur Urol Focus       Date:  2017-05-31

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort.

Authors:  Atiqullah Aziz; Matthias May; Maximilian Burger; Rein-Jüri Palisaar; Quoc-Dien Trinh; Hans-Martin Fritsche; Michael Rink; Felix Chun; Thomas Martini; Christian Bolenz; Roman Mayr; Armin Pycha; Philipp Nuhn; Christian Stief; Vladimir Novotny; Manfred Wirth; Christian Seitz; Joachim Noldus; Christian Gilfrich; Shahrokh F Shariat; Sabine Brookman-May; Patrick J Bastian; Stefan Denzinger; Michael Gierth; Florian Roghmann
Journal:  Eur Urol       Date:  2013-12-27       Impact factor: 20.096

Review 5.  Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.

Authors:  Valérie Fonteyne; Piet Ost; Joaquim Bellmunt; Jean Pierre Droz; Pierre Mongiat-Artus; Brant Inman; Elena Paillaud; Fred Saad; Guillaume Ploussard
Journal:  Eur Urol       Date:  2017-05-03       Impact factor: 20.096

6.  Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.

Authors:  Stephen A Boorjian; Simon P Kim; Matthew K Tollefson; Alonso Carrasco; John C Cheville; R Houston Thompson; Prabin Thapa; Igor Frank
Journal:  J Urol       Date:  2013-01-09       Impact factor: 7.450

7.  Patient-centered risk stratification of disposition outcomes following radical cystectomy.

Authors:  Jasmir G Nayak; John L Gore; Sarah K Holt; Jonathan L Wright; Matthew Mossanen; Atreya Dash
Journal:  Urol Oncol       Date:  2015-12-31       Impact factor: 3.498

8.  A Simplified Frailty Index to Predict Outcomes After Radical Cystectomy.

Authors:  Niranjan J Sathianathen; Stephanie Jarosek; Nathan Lawrentschuk; Damien Bolton; Badrinath R Konety
Journal:  Eur Urol Focus       Date:  2018-01-20

9.  Optimal management of high-risk T1G3 bladder cancer: a decision analysis.

Authors:  Girish S Kulkarni; Antonio Finelli; Neil E Fleshner; Michael A S Jewett; Steven R Lopushinsky; Shabbir M H Alibhai
Journal:  PLoS Med       Date:  2007-09       Impact factor: 11.069

10.  Reliability of the American Society of Anesthesiologists physical status scale in clinical practice.

Authors:  A Sankar; S R Johnson; W S Beattie; G Tait; D N Wijeysundera
Journal:  Br J Anaesth       Date:  2014-04-11       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.